GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure. |
On February2, 2017, Galectin TherapeuticsInc. made a corporate
presentation via VirtualInvestorConferences.com that contains,
among other information, a summary of development of GR-MD-02 for
Non-Alcoholic
Steatohepatitis (NASH) With Advanced Fibrosis and Cirrhosis,
which presentation is attached as Exhibit 99.1.
The information in
this report is being furnished to this Item7.01 and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, and it shall not be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or under the Exchange Act, whether made before or after
the date hereof, except as expressly set forth by specific
reference in such filing to this report.
SECTION9
FINANCIAL STATEMENTS AND EXHIBITS
| Item9.01 | Financial Statements and Exhibits. |
(d)
Exhibits.
|
Exhibit Number |
Description |
|
| 99.1 | Corporate presentation |
– 2 –
About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies. GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Recent Trading Information
GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) closed its last trading session down -0.020 at 0.990 with 328,431 shares trading hands.